Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eDREAM phase 2 trial of GAL-101 ophthalmic solution for non-foveal geographic atrophy secondary to dry AMD
MOH_2025-03-17_013974Phase 2Recruiting
- Sponsor
- Galimedix Therapeutics
- Start
- Mar 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dry age-related macular degeneration and age-related macular degeneration (AMD) comparing GAL-101 with Placebo (2 arms). Primary endpoint: Rate of change in geographic atrophy lesion size. Started Mar 2025; status: recruiting.
02
Drugs
gal-101
03
Conditions
dry age-related macular degenerationage-related macular degeneration (AMD)
Beyond the preview
Go deeper on MOH_2025-03-17_013974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-17_013974.